Processa Pharmaceuticals (PCSA) Cash from Operations (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Cash from Operations came in at 3590695.0 in Q1 2026, down 31.53% YoY from 5244540.57 in Q1 2025, and down 23.82% on a QoQ basis from 2900000.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Cash from Operations (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Cash from Operations data on file, last reported at 3590695.0 in Q1 2026.
- Quarterly Cash from Operations fell 31.53% year-over-year to 3590695.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12260847.0 (down 2.81% YoY) and the FY2025 annual result came in at 11400000.0, down 1.38% from the prior year.
- Cash from Operations eased to 3590695.0 in Q1 2026, from 2900000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1760939.0 in Q3 2023 to a low of 3602608.0 in Q3 2024.
- A 5-year average of 2582601.53 and a median of 2330513.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 40.8% — and 2024, when it sank 104.58%.
- Tracing PCSA's Cash from Operations over 5 years: stood at 2497385.0 in 2022, then climbed by 14.96% to 2123868.0 in 2023, then dropped by 5.83% to 2247721.0 in 2024, then slipped by 29.02% to 2900000.0 in 2025, then retreated by 23.82% to 3590695.0 in 2026.
- The last three Cash from Operations figures came in at 3590695.0 (Q1 2026), 2900000.0 (Q4 2025), and 3500000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 728.46 Mn |
| 10 | Processa Pharmaceuticals | 5.72 Mn | 5.72 Mn | - | -1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.59 Mn |
| Mar 31, 2026 | -3.59 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -2.73 Mn |
| Mar 31, 2025 | -2.73 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |